Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics

作者： Fritz Sörgel , Arnd Schwebig , Johann Holzmann , Stefan Prasch , Pritibha Singh

DOI: 10.1007/S40259-015-0124-7

关键词: Biosimilar 、 Filgrastim 、 Granulocyte colony-stimulating factor 、 Biosimilar Pharmaceuticals 、 Pharmacodynamics 、 Pharmacokinetics 、 Pharmacology 、 Medicine

摘要: Background Biosimilars provide safety, purity, and potency similar to those of a reference biologic product.

参考文章(9)

Arthur J Chirino, Anthony Mire-Sluis, Characterizing biological products and assessing comparability following manufacturing changes Nature Biotechnology. ,vol. 22, pp. 1383- 1391 ,(2004) , 10.1038/NBT1030

Johann Holzmann, Anna Hausberger, Alfred Rupprechter, Hansjoerg Toll, Top-down MS for rapid methionine oxidation site assignment in filgrastim Analytical and Bioanalytical Chemistry. ,vol. 405, pp. 6667- 6674 ,(2013) , 10.1007/S00216-013-7138-0

M McCamish, G Woollett, The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary? Clinical Pharmacology & Therapeutics. ,vol. 93, pp. 315- 317 ,(2013) , 10.1038/CLPT.2013.17

Fritz Sörgel, Helmut Lerch, Thomas Lauber, Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product BioDrugs. ,vol. 24, pp. 347- 357 ,(2010) , 10.2165/11585100-000000000-00000

Jan Visser, Isabel Feuerstein, Thomas Stangler, Timo Schmiederer, Cornelius Fritsch, Martin Schiestl, Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab BioDrugs. ,vol. 27, pp. 495- 507 ,(2013) , 10.1007/S40259-013-0036-3

Karl Verpoort, Thomas M. Möhler, A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Therapeutic Advances in Medical Oncology. ,vol. 4, pp. 289- 293 ,(2012) , 10.1177/1758834012461330

P. Gascon, U. Fuhr, F. Sörgel, M. Kinzig-Schippers, A. Makhson, S. Balser, S. Einmahl, M. Muenzberg, Development of a new G-CSF product based on biosimilarity assessment Annals of Oncology. ,vol. 21, pp. 1419- 1429 ,(2010) , 10.1093/ANNONC/MDP574

Pere Gascón, Hans Tesch, Karl Verpoort, Maria Sofia Rosati, Nello Salesi, Samir Agrawal, Nils Wilking, Helen Barker, Michael Muenzberg, Matthew Turner, Clinical experience with Zarzio® in Europe: what have we learned? Supportive Care in Cancer. ,vol. 21, pp. 2925- 2932 ,(2013) , 10.1007/S00520-013-1911-7

Erwin A. Blackstone, Joseph P. Fuhr, Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnology healthcare. ,vol. 9, pp. 24- 27 ,(2012)